phrykt

Outlook Therapeutics, Inc. (OTLK): who owns it and who trades it

As of Nov 16, 2026, OTLK insiders reported 8 purchases worth $7.9M in the last 12 months. The largest buyer was GMS Ventures & Investments (Director), with $5M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Outlook Therapeutics

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns OTLK

68 funds and institutions reported OTLK shares worth $32.5M at the end of Q2 2026, about 17% of the company. The largest holder is Vanguard Capital Management LLC with 3.6%.

Funds and institutions (13F) 17%Everyone else 83%

10 largest owners, by share of the company

Vanguard Capital Management LLC3.6%
Perceptive Advisors LLC2.6%
Marshall Wace, LLP1.6%
BlackRock, Inc.1.4%
Jane Street Group, LLC1.2%
Geode Capital Management, LLC1.0%
Susquehanna International Group, LLP0.8%
Hrt Financial LP0.6%
Vanguard Fiduciary Trust Co0.5%
Gilpin Wealth Management, LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC4.38M3.62%$7M–
Perceptive Advisors LLC3.14M2.60%$5M–
Marshall Wace, LLP1.99M1.64%$3.2M–
BlackRock, Inc.1.67M1.38%$2.7M–
Jane Street Group, LLC1.43M1.18%$2.3M–
Geode Capital Management, LLC1.25M1.03%$2M–
Susquehanna International Group, LLP968,1900.80%$1.5M–
Hrt Financial LP784,9040.65%$1.2M–
Vanguard Fiduciary Trust Co661,6640.55%$1.1M–
Gilpin Wealth Management, LLC555,0000.46%$882K–
State Street Corp539,8020.45%$858K–
Cantor Fitzgerald, L. P.450,0000.37%$716K–
Sanctuary Advisors, LLC344,5290.29%$548K–
Raymond James Financial Inc332,0510.27%$528K–
Group One Trading LLC246,4280.20%$392K–
Northern Trust Corp237,5610.20%$378K–
Simplex Trading, LLC205,0130.17%$326K–
LPL Financial LLC184,9420.15%$294K–
UBS Group AG152,2150.13%$242K–
Deutsche Bank Ag\130,7000.11%$208K–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, OTLK insiders reported $7.9M of open-market purchases and $0 of sales.

Purchases, 12 months
$7.9M
8 trades, 6 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 12, 2026
Filed Aug 14, 2026

Purchases and sales by month

$5.3M$5.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 12, 2026Ghiath M. Sukhtian +1DirectorPurchase2.53M$0.99$2.5MForm 4
Jul 29, 2026Faisal Ghiath SukhtianDirectorPurchase95,398$1.05$100KForm 4
Jun 2, 2026Yezan Munther HaddadinDirectorPurchase29,000$0.83$24.1KForm 4
May 28, 2026GMS Ventures & Investments +1DirectorPurchase8.54M$0.59$5MForm 4
May 27, 2026Faisal Ghiath SukhtianDirectorPurchase122,174$0.41$50.1KForm 4
May 26, 2026Yezan Munther HaddadinDirectorPurchase34,000$0.44$15KForm 4
May 26, 2026Randy H ThurmanDirectorPurchase5,000$0.43$2.1KForm 4
May 26, 2026Kurt J HilzingerDirectorPurchase400,000$0.44$176KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
GMS Ventures & InvestmentsDirector, 10% owner$5M–May 28, 2026
Ghiath M. SukhtianDirector, 10% owner$2.5M–Aug 12, 2026
Kurt J HilzingerDirector$176K–May 26, 2026
Faisal Ghiath SukhtianDirector$150K–Jul 29, 2026
Yezan Munther HaddadinDirector$39K–Jun 2, 2026
Randy H ThurmanDirector$2.1K–May 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OTLK short interest

High short interest. 14.6% of OTLK shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 291%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 35.55M OTLK shares were sold short, 14.6% of the shares outstanding, up 9.1% from the report before. At the average daily volume of 3.52M shares, buying them all back would take about 10.1 trading days (days to cover).

Shares short, % of all shares

14.6%May 15Oct 3017.9%

Days to cover

10.1May 15Oct 3011.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202635.55M14.60%+9%3.52M10.1
Oct 15, 202632.59M13.39%+2%4.77M6.8
Sep 30, 202631.90M13.10%-1%4.49M7.1
Sep 15, 202632.22M13.24%-2%4.20M7.7
Aug 31, 202632.91M13.52%+65%20.06M1.6
Aug 14, 202619.90M8.17%-1%24.24M1.0
Jul 31, 202620.01M16.56%+78%18.34M1.1
Jul 15, 202611.24M9.30%-20%9.10M1.2
Jun 30, 202614.01M11.60%+3%15.86M1.0
Jun 15, 202613.58M11.23%-16%21.41M1.0
May 29, 202616.13M13.35%+78%65.46M1.0
May 15, 20269.09M7.52%+41%4.15M2.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Outlook Therapeutics company events

Outlook Therapeutics filed 30 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing). The latest was on Sep 30, 2026.

  1. Sep 30, 2026ListingOutlook Therapeutics, Inc., a Delaware corporation, received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum… Filing
  2. Sep 18, 2026AnnouncementOutlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial. Filing
  3. Aug 27, 2026LeadershipOutlook Therapeutics, Inc. and Lawrence A. Kenyon, the Company’s Chief Financial Officer, Treasurer and Corporate Secretary and a member of the Company’s Board of Directors, mutually agreed that Mr. Kenyon would cease serving in the roles of Chief Financial Officer, Treasurer, Corporate Secretary… Filing
  4. Aug 14, 2026AnnouncementOutlook Therapeutics, Inc. entered into an underwriting agreement with Piper Sandler & Co. and BTIG, LLC, as representatives of the several underwriters named therein, relating to the public offering by the Company of (i) 55,555,556 shares of the Company’s common stock, par value $0.01 per share… Filing
  5. Aug 14, 2026ResultsReleased financial results. Filing
  6. Aug 12, 2026AnnouncementThe Company announced that the U.S. Food and Drug Administration had approved LYTENAVA ™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. In connection with the FDA approval, the Company is amending and restating its risk… Filing
  7. Jul 24, 2026AnnouncementOutlook Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) approved the Company’s biologics license application for ONS-5010/LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab, for the treatment of neovascular (wet) age-related… Filing
  8. Jul 24, 2026LeadershipThe Compensation Committee of the Board of Directors of Outlook Therapeutics, Inc. approved the grant of stock options to purchase shares of the Company’s common stock to the Company’s named executive officers as follows: Robert C. Jahr, the Company’s Chief Executive Officer – 100,000 options and… Filing
  9. Jul 16, 2026VoteReported shareholder vote results. Filing
  10. Jun 26, 2026ListingAs previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation, received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that Nasdaq staff had determined to delist the Company’s common stock, par value $0.01 per… Filing
  11. Jun 16, 2026AnnouncementOutlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration had acknowledged receipt of its resubmission of the Biologics License Application for ONS-5010 (bevacizumab-vikg). Filing
  12. Jun 1, 2026AnnouncementOutlook Therapeutics, Inc issued a press release announcing that it has resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration. Filing
  13. May 29, 2026AnnouncementExhibits are filed herewith in connection with the registered direct offering by Outlook Therapeutics, Inc. of 8,539,709 shares of the Company’s common stock, $0.01 par value per share, to GMS Ventures and Investments pursuant to that certain securities purchase agreement entered into on May 28… Filing
  14. May 28, 2026AnnouncementOutlook Therapeutics, Inc. entered into a securities purchase agreement with GMS Ventures and Investments, pursuant to which the Company agreed to issue and sell to the Purchaser, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, 8,539,709 shares of… Filing
  15. May 26, 2026AnnouncementOutlook Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted the Company's appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND) regarding the December 30, 2025 Complete Response… Filing
  16. May 18, 2026ResultsReleased financial results. Filing
  17. May 13, 2026AgreementOutlook Therapeutics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share, from time to time through H.C. Wainwright as sales agent and/or principal having an… Filing
  18. Apr 23, 2026AnnouncementBelow which is hereby incorporated in this Item 3.02 by reference. Filing
  19. Apr 21, 2026AnnouncementOutlook Therapeutics, Inc issued a press release announcing that it has conducted the requested Federal Dispute Resolution meeting with the Office of New Drugs at the U.S. Food and Drug Administration (FDA) to appeal the complete response letter (CRL) dated December 30, 2025 regarding the biologics… Filing
  20. Apr 7, 2026AnnouncementOutlook Therapeutics, Inc. issued a press release announcing that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics… Filing
  21. Mar 25, 2026AnnouncementOutlook Therapeutics, Inc. commenced a best-efforts public offering of its common stock and accompanying warrants to purchase shares of common stock. Filing
  22. Mar 16, 2026AgreementOutlook Therapeutics, Inc. entered into a Note Purchase Agreement with Atlas Sciences, LLC, a Utah limited liability company, pursuant to which the Company agreed to issue to the Investor an unsecured promissory note with an original principal balance of $18.36 million. Filing
  23. Mar 11, 2026LeadershipThe Board of Directors of Outlook Therapeutics, Inc. accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. Filing
  24. Mar 10, 2026VoteReported shareholder vote results. Filing
  25. Mar 5, 2026AnnouncementOutlook Therapeutics, Inc issued a press release announcing that it has conducted the requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated December 30, 2025 regarding the biologics license application (BLA) resubmission for… Filing
  26. Feb 18, 2026ListingOutlook Therapeutics, Inc., a Delaware corporation, received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum… Filing
  27. Feb 17, 2026ResultsReleased financial results. Filing
  28. Feb 11, 2026AnnouncementOutlook Therapeutics, Inc issued a press release announcing that it has requested a Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated December 31, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an… Filing
  29. Jan 2, 2026AnnouncementOutlook Therapeutics, Inc issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter to the Company’s biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. The… Filing
  30. Dec 19, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Outlook Therapeutics financials

Famous investors that hold OTLK

3 of the 50 well-known investors we track reported holding OTLK in their latest 13F filing. The largest position is Jim Simons's, worth $643K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.12M$643K0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026138,818$79.6K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 2026132,217$75.8K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OTLK in the last 120 days.

FiledHolderFormStake
Nov 16, 2026CVI Investments, Inc.13G/A7.9%
Nov 16, 2026CVI Investments, Inc.13G/A7.9%
Oct 13, 2026Empery Asset Management, LP13G8.7%
Oct 13, 2026Empery Asset Management, LP13G8.7%

Questions about Outlook Therapeutics, Inc. (OTLK) stock

Who owns the most OTLK stock?

The largest reported owner of Outlook Therapeutics, Inc. (OTLK) is Vanguard Capital Management LLC, with 3.6% of the company. In total, 68 funds and institutions reported holding OTLK at the end of Q2 2026, together about 17% of the shares. See the largest owners.

Are OTLK insiders buying or selling?

In the last 12 months, OTLK insiders reported 8 open-market purchases worth $7.9M and no sales. The latest trade was on Aug 12, 2026. See every trade.

What is the short interest in OTLK?

As of Oct 30, 2026, 35.55M OTLK shares were sold short, 14.6% of the shares outstanding, up 9.1% from the report before. At the average daily volume of 3.52M shares, buying them all back would take about 10.1 trading days (days to cover). See the history.

Which famous investors hold OTLK?

3 of the 50 well-known investors we track reported OTLK in their latest 13F filing, including Jim Simons, Ken Griffin, Paul Tudor Jones. The largest position is worth $643K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.